Biomimetic "Water Barrier" Hydrogel for Biopharmaceutical Stabilization and Cold Chain Optimization

What it is Gel Coat Biomaterials (a University of Tokyo spin-off) offers "Gel Coat", a novel biomimetic hydrogel technology that acts as a protective "water barrier" to stabilize biopharmaceuticals and diagnostic reagents. The material is designed based on the mimicry of cell membrane lipid bilayers using a safe, zwitterionic structure.

Why it matters Biopharmaceuticals now account for over 50% of all drugs, yet 90% of them rely on strict freezing (e.g., -30°C) for transport and storage. This dependency causes over 5 trillion JPY in global losses annually, with 10% of drugs discarded due to degradation. By utilizing our technology, manufacturers can shift storage requirements from deep-freezing (-30°C) to standard refrigeration (4°C), room temperature, or even body temperature (37°C). This drastically reduces equipment/electricity costs, eliminates waste, and makes life-saving therapies accessible in low- and middle-income countries where cold-chain infrastructure is lacking.

How it works The biomimetic hydrogel envelops sensitive biological molecules—such as mRNA, DNA, LNPs, enzymes, vaccines, and monoclonal antibodies—in a robust hydration layer that suppresses thermal degradation. Because its chemical structure mimics natural cell membranes, the material is highly biocompatible. It demonstrates no cytotoxicity, shows no abnormalities in in-vivo implantation, is designed for high body excretion, and shares safety profiles with polymers already clinically approved for artificial joints.

Proof to date Thermal Stabilization: Proven to suppress degradation and maintain stability of biologicals at room temperature (RT) and up to 37°C, enabling easy transport and handling without strict temperature controls.

Broad Applicability: Capable of stabilizing a wide range of modalities, including insulin, peptides, hormones, and diagnostic kits at RT, as well as mRNA, DNA, and vaccines under refrigeration/long-term freezing.

New Formulation Enabler: The stabilization effect enables the development of next-generation modalities, such as microneedle skin patches, oral administration forms, and high-concentration injections.

Next steps Our primary target partners are Contract Development and Manufacturing Organizations (CDMOs). We aim to partner with CDMOs to integrate our stabilization technology into their processes, offering it as a new, differentiated product grade to mega-pharma clients. Our business model progresses from paid sample provision to paid joint development, contract development, and ultimately licensing and royalty agreements, sharing the massive cost-reduction value created.